Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02162420 · ClinicalTrials.gov registry record · NA
Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
A NA study of Aplastic Anemia and Dyskeratosis Congenita, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT02162420 is a NA study of Aplastic Anemia and Dyskeratosis Congenita that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 61 participants, above the 40-participant average among 23 other Aplastic Anemia trials with a reported enrollment target (53% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02162420, a NA study of Aplastic Anemia and Dyskeratosis Congenita, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
Fludarabine-based preparative regimen followed by an allogeneic hematopoietic stem cell transplant using related or unrelated donor in persons 0-70 years of age diagnosed with dyskeratosis congenita or severe aplastic anemia who have bone marrow failure characterized by a requirement for red blood cell and platelet transfusions. Three different preparative regimens are included based on disease and donor type.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Alemtuzumab
- RADIATION Total Body Irradiation
- BIOLOGICAL Stem Cell Transplant
Study Locations (1)
Minnesota
- University of Minnesota Medical Center, Fairview - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2015-01-10 |
| Est. Completion | 2025-03-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02162420
The ClinicalTrials.gov registry entry for NCT02162420 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 40-participant average among 23 other Aplastic Anemia trials with a reported enrollment target (53% higher). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Aplastic Anemia appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02162420 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02162420 about?
NCT02162420 is a clinical study titled "Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia". Fludarabine-based preparative regimen followed by an allogeneic hematopoietic stem cell transplant using related or unrelated donor in persons 0-70 years of age diagnosed with dyskeratosis congenita or severe aplastic anemia who have bone marrow failure characterized by a requirement for red blood c...
What is the current status of trial NCT02162420?
This trial is currently completed. It is a NA study. The enrollment target is 61 participants. The study started on 2015-01-10. Estimated completion is 2025-03-11.
What conditions does trial NCT02162420 study?
This clinical trial studies the following conditions: Aplastic Anemia, Dyskeratosis Congenita.
What interventions are being tested in trial NCT02162420?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Alemtuzumab (DRUG), Total Body Irradiation (RADIATION), Stem Cell Transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT02162420?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02162420 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aplastic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
-
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
ACTIVE NOT RECRUITING · NA
-
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
COMPLETED · NA
-
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RECRUITING · Early Phase 1
-
Two Step Haplo With Radiation Conditioning
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.